Efficacy and safety of HER2 directed therapies for advanced HER2-mutant non-small-cell lung cancer - a systematic review and meta-analysis.
Tyrosine kinase inhibitors show higher response rates and better tolerability than antibody-drug conjugates for advanced lung cancers with HER2 mutations.
The primary outcome was objective response rates (ORRs). CONCLUSION: HER2 TKIs may be the preferred initial option over ADCs in advanced HER2 mutated NSCLC, given their higher response rates, particularly in YVMA insertions, a more favorable safety profile, and preserved ADC efficacy following TKI exposure.
What the study was
- Study design
- Prospective Cohort
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Why it surfaced
Matched watchlist: Novel therapeutics: immunother; scored 7/10 based on abstract-level review; design=Prospective Cohort; species=human; flag=PROMISING_PRELIMINARY.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.